CureVac Abandons First Covid Shot After Disappointing Trial
- German biotech will focus on second-generation vaccine instead
- Millions EU paid for vaccine order won’t need refunding: CEO
This article is for subscribers only.
CureVac NV is abandoning its first-generation Covid-19 vaccine to focus on another shot it’s developing together with GlaxoSmithKline Plc.
European regulatory authorities had indicated the vaccine probably wouldn’t be approved before the second quarter of next year, the German biotech said on Tuesday. By then, CureVac and Glaxo expect to be conducting late-stage patient trials of a second-generation shot. The company’s advanced purchase agreement with the European Commission will be cancelled as a result.